Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.…
Zentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Updates
Zentalis Pharmaceuticals (NASDAQ: ZNTL) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 106 employees.
The shares were at 1.360 USD on 20 November 2026, up 6.3% over 52 weeks. Its 52-week range is 1.250 USD to 6.950 USD: the price is 80.4% below the high and 8.8% above the low.
Its market capitalisation is 133.64M USD.
Zentalis Pharmaceuticals reports return on equity of -63.4% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 192.18M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 25 March 2027.